Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “TEVA PHARMACEUTICAL INDUSTRIES, LTD.”

302 pharma patents match "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 302
Index total 30,257
Page 1 / 13

Quick answer

This filtered view shows 302 pharmaceutical patents matching "TEVA PHARMACEUTICAL INDUSTRIES, LTD." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

302 results for “TEVA PHARMACEUTICAL INDUSTRIES, LTD.” · 30,257 patents in full index Clear search

  1. US 12310929

    Use of rasagiline for the treatment of restless legs syndrome

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 27, 2025 · Expires May 22, 2045

    granted
  2. US 11472772

    S1P3 antagonists

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 18, 2022 · Expires Oct 13, 2042

    granted
  3. US 11135154

    Medroxyprogesterone acetate injectable compositions and methods of use

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted
  4. US 10130621

    Analogs of pridopidine, their preparation and use

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted
  5. US 9951017

    S1P3 antagonists

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  6. US 9763993

    Process for manufacturing glatiramer acetate product

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted
  7. US 9702007

    Genetic markers predictive of response to glatiramer acetate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jul 11, 2017 · Expires Jul 6, 2037

    granted
  8. US 9687522

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jun 27, 2017 · Expires Jun 22, 2037

    granted
  9. US 9662322

    Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 30, 2017 · Expires May 25, 2037

    granted
  10. US 9625473

    Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted
  11. US 9617596

    Biomarkers predictive for clinical response for glatiramer acetate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted
  12. US 9585878

    Treatment of BDNF-related disorders using laquinimod

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 7, 2017 · Expires Mar 2, 2037

    granted
  13. US 9499868

    Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 22, 2016 · Expires Nov 17, 2036

    granted
  14. US 9409662

    Formulations of albu-BChE, preparation and uses thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Aug 9, 2016 · Expires Aug 4, 2036

    granted
  15. US 9375403

    Formulations of 6-mercaptopurine

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jun 28, 2016 · Expires Jun 23, 2036

    granted
  16. US 9346746

    R(+)-N-formyl-propargyl-aminoindan

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 24, 2016 · Expires May 19, 2036

    granted
  17. US 9339469

    R(+)-N-methyl-propargyl-aminoindan

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 17, 2016 · Expires May 12, 2036

    granted
  18. US 9340307

    Stable laquinimod preparations

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 17, 2016 · Expires May 12, 2036

    granted
  19. US 9308182

    Parenteral formulations of rasagiline

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 12, 2016 · Expires Apr 7, 2036

    granted
  20. US 9284276

    N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 15, 2016 · Expires Mar 10, 2036

    granted
  21. US 9233927

    Crystals of laquinimod sodium and improved process for the manufacture thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  22. US 9186333

    Process for preparing pharmaceutical compositions of fingolimod

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 17, 2015 · Expires Nov 12, 2035

    granted
  23. US 9180097

    Formulations of 6-mercaptopurine

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 10, 2015 · Expires Nov 5, 2035

    granted
  24. US 9161936

    Laquinimod for treatment of GABA mediated disorders

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Oct 20, 2015 · Expires Oct 15, 2035

    granted